Earlier this month Astrazeneca applied to the FDA for an emergency use authorisation (EUA) for its long-acting monoclonal antibody cocktail AZD7442. The application is based on the results of the PROVENT phase 3 trial of the drug as a prophylactic against Covid19, backed up by laboratory studies, purporting to show the drug's neutralising activity against the Delta and Mu variants, and safety data from the STORM CHASER trials.
More recently Astrazeneca has begun submitting data to the European Medicines Agency (EMA) under a "Rolling Review" arrangement. This is a fairly common way of fast-tracking a promising drug towards a formal marketing authorisation, but it tells us that some of the key data are not yet there. My guess is that EMA/ Astrazeneca want to have enough subjects monitored for 12 months to be able to demonstrate that protection is indeed "long acting" as billed. Another requirement could be confirming real-world protection against the Delta variant, which appeared circa mid 2021 in the PROVENT trial locations.
Oh, the name. Evusheld. Really. ema.europa.eu/en/news/ema-s...